Verastem (VSTM) 10-K2022 FY Annual report

Filed: 14 Mar 23, 5:00pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: ABRAXANE, accreted, acknowledging, acneiform, affirmative, aforementioned, antitumor, appeal, ARAF, avutometinib, Baker, Bank, banking, basal, Becerra, bevacizumab, BICR, biosimilar, blocker, Bloomberg, Bryant, BVF, California, Catalyst, cervical, CFGI, Circuit, Clara, color, contra, Cotellic, CPK, CRAF, cut, dilatation, dissolution, Distinguishing, dominant, drawdown, edema, Eisai, eleven, empowered, endocrine, enzyme, Erasca, erode, exarafenib, extracellular, FDIC, FDORA, foreclose, GEMZAR, harboring, hybrid, Indonesia, inflammation, involuntarily, IRA, junior, Koselugo, KRAZATI, KRAZTI, lend, longstanding, Malaysia, matrix, mediate, melanin, mild, movement, MSI, negligent, neuroblastoma, nonprovisional, ODAC, OFCF, OS, outlined, PanCAN, pari, parity, passu, path, phosphokinase, pigment, pledge, prespecified, pretreated, PwC, ranking, ransomware, recapitalization, receivership, regression, rest, RhoA, Santa, Silicon, SPV, stable, sun, SVB, systematic, TCJA, tie, ultraviolet, unconfirmed, uninsured, untreated, upcoming, UV, Valley, vast, voluntarily, wholly, YAP, yearly, Zelboraf

Removed: begun, Bentley, Biogen, Bioscience, Bipartisan, branch, Clean, College, cumulatively, defer, delisted, Deloitte, directing, expressly, female, FL, Gagnon, growing, Harvard, Idec, incidence, intraperiod, invasive, joined, MICL, MIT, organ, peak, RAS, rating, Robert, School, Secretary, Simplifying, Sloan, structurally, subordinated, suggest, sweeping, syndrome, TME, Touche, Treasurer, waiting, waive, watchful

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

VSTM similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1)

Registration Statement (Form S-8 No. 333-180475) pertaining to the 2010 Equity Incentive Plan and the 2012 Incentive Plan of Verastem, Inc.,

(2)

Registration Statement (Form S-8 No. 333-190578) pertaining to the 2012 Incentive Plan of Verastem, Inc.,

(3)

Registration Statement (Form S-8 No. 333-201075) pertaining to the 2014 Inducement Award Program of Verastem, Inc.,

(4)

Registration Statement (Form S-8 No. 333-201076) pertaining to the 2012 Incentive Plan of Verastem, Inc.,

(5)

Registration Statement (Form S-8 No. 333-211235) pertaining to the 2012 Incentive Plan of Verastem, Inc.,

(6)

Registration Statement (Form S-8 No. 333-218768) pertaining to the 2014 Inducement Award Program of Verastem, Inc.,

(7)

Registration Statement (Form S-8 No. 333-218769) pertaining to the 2012 Incentive Plan of Verastem, Inc.,

(8)

Registration Statement (Form S-8 No.333-223616) pertaining to the 2014 Inducement Award Program of Verastem, Inc.,

(9)

Registration Statement (Form S-8 No.333-228309) pertaining to the 2014 Inducement Award Program of Verastem, Inc.,

(10)

Registration Statement (Form S-8 No.333-229430) pertaining to the 2018 Employee Stock Purchase Plan, 2012 Amended and Restated Incentive Plan, and 2014 Inducement Award Program of Verastem, Inc.,

(11)

Registration Statement (Form S-8 No. 333-238877) pertaining to the 2012 Amended and Restated 2012 Incentive Plan of Verastem, Inc.,

(12)

Registration Statement (Form S-3 No. 333-237332) of Verastem, Inc.,

(13)

Registration Statement (Form S-8 No. 333-257111) pertaining to the 2021 Equity Incentive Plan of Verastem, Inc. and,

(14)

Registration Statement (Form S-3 No. 333-258372) of Verastem, Inc.

of our report dated March 14, 2023 with respect to the consolidated financial statements of Verastem, Inc. included in this Annual Report (Form 10-K) of Verastem, Inc. for the year ended December 31, 2022.

/s/ Ernst & Young LLP

Boston, Massachusetts

March 14, 2023

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.